Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 05-Dec-13 3:14 PM View:  | Thompson Virgil Director | Savient Pharmaceuticals Inc. (SVNTQ) | 04-Dec-13 | Sale | 106,751 | $0.02 | $2,455.27 | (100%) 106.75K to 0 | |
| 18-Oct-13 4:34 PM View: | Jaeger Stephen O Director | Savient Pharmaceuticals Inc. (SVNTQ) | 17-Oct-13 | Sale | 38,061 | $0.05 | $1,903.05 | (100%) 38.06K to 0 | |
| 21-Oct-13 5:05 PM View: | Constantine Ginger Director | Savient Pharmaceuticals Inc. (SVNTQ) | 16-Oct-13 | Market Sale | 8,805 | $0.07 | $639.24 | (100%) 8.8K to 0 | 39% |
| 17-Oct-13 11:20 AM View: | Bahrt Kenneth SVP, Chief Medical Officer | Savient Pharmaceuticals Inc. (SVNTQ) | 16-Oct-13 | Market Sale | 8,000 | $0.07 | $589.25 | (7%) 108.0K to 100.0K | 19% |
| 17-Oct-13 11:31 AM View: | Crowley Richard Co-President and COO | Savient Pharmaceuticals Inc. (SVNTQ) | 15-Oct-13 | Market Sale | 113,740 | $0.08 | $8,638.66 | (40%) 285.49K to 171.75K | 24% |
| 17-Oct-13 11:20 AM View: | Bahrt Kenneth SVP, Chief Medical Officer | Savient Pharmaceuticals Inc. (SVNTQ) | 15-Oct-13 | Market Sale | 70,211 | $0.08 | $5,712.13 | (39%) 178.21K to 108.0K | 29% |
| 17-Oct-13 1:17 PM View: | Hamill John Co-President and CFO | Savient Pharmaceuticals Inc. (SVNTQ) | 15-Oct-13 | Market Sale | 36,946 | $0.08 | $2,938.62 | (36%) 103.61K to 66.67K | 28% |
| 17-Oct-13 11:21 AM View: | Gionco David Chief Accounting Officer | Savient Pharmaceuticals Inc. (SVNTQ) | 15-Oct-13 | Market Sale | 47,876 | $0.08 | $3,855.38 | (57%) 83.64K to 35.76K | 29% |
| 17-Oct-13 2:14 PM View: | Yachmetz Philip K Co-President and CBO | Savient Pharmaceuticals Inc. (SVNTQ) | 15-Oct-13 | Market Sale | 213,156 | $0.10 | $20,835.20 | (70%) 303.7K to 90.55K | 41% |
| 23-May-13 2:36 PM View: | Ferrari Louis President and CEO Director | Savient Pharmaceuticals Inc. (SVNTQ) | 22-May-13 | Market Sale (Planned) | 1,020 | $0.57 | $581.40 | (< 1%) 308.46K to 307.44K | 2% |
| 01-May-13 5:37 PM View: | Bahrt Kenneth SVP, Chief Medical Officer | Savient Pharmaceuticals Inc. (SVNTQ) | 30-Apr-13 | Market Sale (Planned) | 1,250 | $0.74 | $925.00 | (< 1%) 179.46K to 178.21K | 24% |
| 01-May-13 5:36 PM View: | Crowley Richard EVP, Chief Operating Officer | Savient Pharmaceuticals Inc. (SVNTQ) | 30-Apr-13 | Market Sale (Planned) | 2,485 | $0.74 | $1,838.90 | (< 1%) 287.98K to 285.49K | 24% |
| 08-Mar-13 4:15 PM View: | Gionco David Group VP & Chief Acct. Officer | Savient Pharmaceuticals Inc. (SVNTQ) | 06-Mar-13 | Market Sale (Planned) | 1,560 | $0.93 | $1,450.80 | (2%) 85.2K to 83.64K | 40% |
| 07-Mar-13 4:51 PM View: | Gionco David Group VP & Chief Acct. Officer | Savient Pharmaceuticals Inc. (SVNTQ) | 05-Mar-13 | Grant | 29,000 | -- | -- | 52% 56.2K to 85.2K | |
| 25-Feb-13 4:35 PM View: | Ferrari Louis President and CEO Director | Savient Pharmaceuticals Inc. (SVNTQ) | 25-Feb-13 | Market Sale (Planned) | 375 | $0.99 | $371.25 | (< 1%) 296.37K to 296.0K | 43% |
| 06-Feb-13 10:18 AM View: | Crowley Richard EVP, Biopharmaceutical Ops | Savient Pharmaceuticals Inc. (SVNTQ) | 04-Feb-13 | Market Sale (Planned) | 48,900 | $1.03 | $50,589.00 | (15%) 336.88K to 287.98K | 46% |
| 06-Feb-13 10:17 AM View: | Ferrari Louis President and CEO Director | Savient Pharmaceuticals Inc. (SVNTQ) | 04-Feb-13 | Market Sale (Planned) | 62,200 | $1.01 | $62,854.00 | (17%) 358.57K to 296.37K | 45% |
| 06-Feb-13 10:19 AM View: | Bahrt Kenneth SVP, Chief Medical Officer | Savient Pharmaceuticals Inc. (SVNTQ) | 04-Feb-13 | Market Sale (Planned) | 29,000 | $1.03 | $29,941.00 | (14%) 200.75K to 171.75K | 46% |
| 06-Feb-13 10:17 AM View: | Yachmetz Philip K SVP, General Counsel | Savient Pharmaceuticals Inc. (SVNTQ) | 04-Feb-13 | Market Sale (Planned) | 30,500 | $1.01 | $30,837.00 | (9%) 334.2K to 303.7K | 45% |
| 04-Feb-13 1:57 PM View: | Bahrt Kenneth SVP, Chief Medical Officer | Savient Pharmaceuticals Inc. (SVNTQ) | 31-Jan-13 | Market Sale (Planned) | 1,300 | $1.03 | $1,339.00 | (< 1%) 202.05K to 200.75K | 46% |
| 04-Feb-13 1:57 PM View: | Crowley Richard EVP, Biopharmaceutical Ops | Savient Pharmaceuticals Inc. (SVNTQ) | 31-Jan-13 | Market Sale (Planned) | 2,415 | $1.02 | $2,463.30 | (< 1%) 339.29K to 336.88K | 45% |
| 16-Jan-13 4:07 PM View: | Yachmetz Philip K SVP, General Counsel | Savient Pharmaceuticals Inc. (SVNTQ) | 14-Jan-13 | Market Sale (Planned) | 1,283 | $1.14 | $1,462.62 | (< 1%) 335.48K to 334.2K | 51% |
| 17-Jan-13 11:22 AM View: | Meeker David P Director | Savient Pharmaceuticals Inc. (SVNTQ) | 07-Jan-13 | Grant | 12,644 | $1.17 | $14,793.50 | 100% 0 to 12.64K | (52%) |
| 07-Dec-12 4:16 PM View: | Savage Robert G Director | Savient Pharmaceuticals Inc. (SVNTQ) | 05-Dec-12 | Grant | 16,149 | $1.14 | $18,409.90 | 100% 0 to 16.15K | (51%) |
| 27-Nov-12 4:12 PM View: | Ferrari Louis President and CEO Director | Savient Pharmaceuticals Inc. (SVNTQ) | 26-Nov-12 | Market Sale (Planned) | 950 | $1.16 | $1,102.00 | (< 1%) 359.52K to 358.57K | 52% |
| 06-Nov-12 6:39 PM View: | Bahrt Kenneth SVP, Chief Medical Officer | Savient Pharmaceuticals Inc. (SVNTQ) | 31-Oct-12 | Market Sale (Planned) | 1,000 | $1.45 | $1,450.00 | (< 1%) 203.05K to 202.05K | 61% |
| 06-Nov-12 6:40 PM View: | Crowley Richard EVP, Biopharmaceutical Ops | Savient Pharmaceuticals Inc. (SVNTQ) | 31-Oct-12 | Market Sale (Planned) | 2,010 | $1.45 | $2,914.50 | (< 1%) 341.3K to 339.29K | 61% |
| 26-Sep-12 4:06 PM View: | Hamill John SVP, CFO | Savient Pharmaceuticals Inc. (SVNTQ) | 24-Sep-12 | Grant | 100,000 | $2.92 | $292,000.00 | 100% 0 to 100.0K | (81%) |
| 27-Nov-12 4:12 PM View: | Ferrari Louis President and CEO Director | Savient Pharmaceuticals Inc. (SVNTQ) | 31-Aug-12 | Grant | 2,434 | $1.12 | $2,730.95 | < 1% 357.09K to 359.52K | |
| 24-Aug-12 8:05 PM View: | Ferrari Louis President and CEO Director | Savient Pharmaceuticals Inc. (SVNTQ) | 22-Aug-12 | Market Sale (Planned) | 984 | $1.00 | $985.97 | (< 1%) 349.56K to 348.58K | 44% |
| 03-Aug-12 8:38 AM View: | Crowley Richard EVP, Biopharma Operatiotions | Savient Pharmaceuticals Inc. (SVNTQ) | 02-Aug-12 | Market Sale (Planned) | 2,500 | $0.62 | $1,550.00 | (< 1%) 343.8K to 341.3K | 8% |
| 03-Aug-12 8:38 AM View: | Bahrt Kenneth SVP, Chief Medical Officer | Savient Pharmaceuticals Inc. (SVNTQ) | 01-Aug-12 | Market Sale (Planned) | 4,950 | $0.62 | $3,069.00 | (2%) 208.0K to 203.05K | 8% |
| 20-Jul-12 4:59 PM View: | Norton David Y Director | Savient Pharmaceuticals Inc. (SVNTQ) | 09-Jul-12 | Grant | 62,035 | $0.56 | $34,739.60 | 856% 7.25K to 69.28K | 3% |
| 27-Nov-12 4:12 PM View: | Ferrari Louis President and CEO | Savient Pharmaceuticals Inc. (SVNTQ) | 31-May-12 | Grant | 5,888 | $0.62 | $3,624.65 | 2% 351.2K to 357.09K | |
| 24-May-12 5:16 PM View: | Jaeger Stephen O Director | Savient Pharmaceuticals Inc. (SVNTQ) | 22-May-12 | Grant | 98,765 | $0.81 | $79,999.60 | 148% 66.64K to 165.41K | (29%) |
| 24-May-12 5:16 PM View: | Owen William F Director | Savient Pharmaceuticals Inc. (SVNTQ) | 22-May-12 | Grant | 49,382 | $0.81 | $39,999.40 | 681% 7.25K to 56.63K | (29%) |
| 22-May-12 4:24 PM View: | Ferrari Louis President and CEO | Savient Pharmaceuticals Inc. (SVNTQ) | 22-May-12 | Market Sale (Planned) | 942 | $0.82 | $772.44 | (< 1%) 350.5K to 349.56K | 30% |
| 24-May-12 5:16 PM View: | Thompson Virgil Director | Savient Pharmaceuticals Inc. (SVNTQ) | 22-May-12 | Grant | 49,382 | $0.81 | $39,999.40 | 82% 60.19K to 109.58K | (29%) |
| 24-May-12 5:15 PM View: | Constantine Ginger Director | Savient Pharmaceuticals Inc. (SVNTQ) | 22-May-12 | Grant | 49,382 | $0.81 | $39,999.40 | 316% 15.63K to 65.02K | (29%) |
| 01-May-12 5:02 PM View: | Crowley Richard EVP Biopharmaceutical Operatio | Savient Pharmaceuticals Inc. (SVNTQ) | 01-May-12 | Market Sale (Planned) | 9,200 | $2.35 | $21,620.00 | (3%) 353.0K to 343.8K | 76% |
| 27-Nov-12 4:12 PM View: | Ferrari Louis President and CEO | Savient Pharmaceuticals Inc. (SVNTQ) | 29-Feb-12 | Grant | 2,622 | $1.71 | $4,479.69 | < 1% 348.58K to 351.2K | |
| 29-Feb-12 4:01 PM View: | Yachmetz Philip K SVP, General Counsel | Savient Pharmaceuticals Inc. (SVNTQ) | 27-Feb-12 | Grant | 100,000 | $2.10 | $210,000.00 | 42% 235.48K to 335.48K | (73%) |
| 23-Feb-12 12:22 PM View: | Ferrari Louis EVP, North American Commerical | Savient Pharmaceuticals Inc. (SVNTQ) | 22-Feb-12 | Market Sale (Planned) | 4,100 | $2.06 | $8,446.00 | (1%) 354.6K to 350.5K | 72% |
| 23-Feb-12 12:22 PM View: | Yachmetz Philip K SVP, General Counsel | Savient Pharmaceuticals Inc. (SVNTQ) | 14-Feb-12 | Market Sale (Planned) | 3,540 | $2.02 | $7,150.80 | (1%) 239.02K to 235.48K | 72% |
| 13-Feb-12 6:35 AM View: | Crowley Richard EVP, Biopharmaceutical Ops | Savient Pharmaceuticals Inc. (SVNTQ) | 01-Feb-12 | Grant | 250,000 | $2.26 | $565,000.00 | 243% 103.0K to 353.0K | (75%) |
| 13-Feb-12 6:36 AM View: | Bahrt Kenneth SVP, Chief Medical Officer | Savient Pharmaceuticals Inc. (SVNTQ) | 01-Feb-12 | Grant | 150,000 | $2.26 | $339,000.00 | 259% 58.0K to 208.0K | (75%) |
| 13-Feb-12 6:33 AM View: | Ferrari Louis EVP, N American Commerical Ops | Savient Pharmaceuticals Inc. (SVNTQ) | 01-Feb-12 | Grant | 310,000 | $2.26 | $700,600.00 | 695% 44.6K to 354.6K | (75%) |
| 13-Feb-12 6:34 AM View: | Yachmetz Philip K SVP, General Counsel | Savient Pharmaceuticals Inc. (SVNTQ) | 01-Feb-12 | Grant | 50,000 | $2.26 | $113,000.00 | 26% 189.02K to 239.02K | (75%) |
| 04-Jan-12 4:17 PM View: | Johnson John H Chief Executive Officer Director | Savient Pharmaceuticals Inc. (SVNTQ) | 03-Jan-12 | Market Sale (Planned) | 17,650 | $2.30 | $40,595.00 | (7%) 270.0K to 252.35K | 75% |
| 13-Feb-12 6:33 AM View: | Ferrari Louis EVP, N American Commerical Ops | Savient Pharmaceuticals Inc. (SVNTQ) | 30-Nov-11 | Grant | 381 | $2.13 | $811.53 | < 1% 44.22K to 44.6K |
